Keywords: Cabazitaxel; Metastatic castration-resistant prostate cancer; Rechallenge; Overall survival; Progression-free survival; Taxanes; Safety;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Cabazitaxel; Castration-resistant; Chemotherapy; Clinical trial; Metastatic; Mitoxantrone; Phase 1; Prednisone; Prostate cancer;
Keywords: Polyion complex; Cabazitaxel; Tumor penetration; Nanoparticle; Drug delivery; Charge reversal;
Keywords: Cabazitaxel; Drug-resistance; Nanoparticles; Prostate cancer; Bone metastasis;
Keywords: Homing peptide; Cabazitaxel; Nanomicelles; Metastatic breast cancer; Necrosis;
Keywords: Aged; Metastatic disease; Prostatic neoplasm; Castration-resistant; Chemotherapy; Docetaxel; Cabazitaxel;
Keywords: Abiraterone; Androgen-receptor; Biomarkers; Cabazitaxel; Cell free DNA; Circulating tumor cells; Docetaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes;
Keywords: Prostate neoplasms; Castration-resistant; Biomarkers; Receptors; Androgen; Genetic; Abiraterone acetate; MDV 3100; Docetaxel; Cabazitaxel
Keywords: Castration-resistant prostate cancer; Hormone therapy; Cabazitaxel; Prognostic factors; Consensus; Algorithm;
Keywords: Cabazitaxel (PubChem CID: 9854073); Ethylene glycol (PubChem CID: 174); ε-Caprolactone (PubChem CID: 10401); Stannous octoate (PubChem CID: 9318); Cabazitaxel; Polymeric micelle; Antitumor; Lewis lung carcinoma;
Keywords: Prostate cancer; Castration-resistant; Treatment sequence; Abiraterone; Docetaxel; Enzalutamide; Cabazitaxel; Radium; Biomarkers;
Keywords: Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Estramustine; Thromboembolism
Keywords: Metastatic castration-resistant prostate cancer; Docetaxel; Young; Abiraterone acetate; Cabazitaxel; Enzalutamide;
Keywords: Prostate cancer; Cabazitaxel; Abiraterone acetate; Enzalutamide; Sequential therapy
Keywords: Abiraterone; Cabazitaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes
Keywords: Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Docetaxel; Enzalutamide; Therapy sequence;
Keywords: Castration resistant prostate cancer; Cabazitaxel; Prostate-specific antigen; Chemotherapy; Cytotoxic agents; Survival rate;
Keywords: Prostate cancer; Metastatic; Castration-resistant; Cabazitaxel; Abiraterone; Enzalutamide;
Keywords: Prostate cancer; Docetaxel; Cabazitaxel; Drug toxicity
Keywords: Metastatic castration-resistant prostate cancer; Cabazitaxel; Safety; Senior men; Elderly; Neutropenia; Granulocyte colony-stimulating factor; Supportive care;
Keywords: CRPC; Novel treatments; Abiraterone; Enzalutamide; Cabazitaxel; Sipuleucel T; Radium-223;
Keywords: Metastatic castration-resistant prostate cancer; Consensus; Radium 223 dichloride; Abiraterone; Enzalutamide; Docetaxel; Circulating tumour cells; Sipuleucel-T; Cabazitaxel; Denosumab;
Keywords: Cabazitaxel; Cholesterol; Triglyceride; Phosphatidylcholine; Sphingomyelin; Alcohol; Acetonitrile; Phosphatidylethanolamine; Poloxamer 188Cabazitaxel; Cholesterol; Intravenous lipid emulsion; Formulation; Chemical stability; Degradation kinetics
Keywords: Castration-resistant prostate cancer; Enzalutamide; Abiraterone; Radium-223; Cabazitaxel; Docetaxel; Bone metastases;
Keywords: Prostate cancer; Castration-resistance; Sipuleucel-T; Cabazitaxel; Abiraterone; Enzalutamide; Denosumab
Keywords: Drug delivery systems design; Physicochemistry; Biopharmacy; Pharmacokinetics; Pharmacodynamics; Efficacy; Safety; Taxanes; Classification; Paclitaxel; Docetaxel; Cabazitaxel; Nanoparticles;
Keywords: Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Keywords: Nanomedicine; Nanoamorphization; CO2; Itraconazole; Cabazitaxel
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Keywords: Castration-resistant prostate cancer; Cabazitaxel; Dosing schedule; Dose intensity;
Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia
Keywords: ALL; acute lymphoblastic leukemia; BM; bone marrow; MRD; minimal residual disease; CAB; cabazitaxel; PLI; plicamycin; NP; nanoparticles; PD; phase dim; B-cell acute lymphoblastic leukemia; Bone marrow microenvironment; Minimal residual disease; Drug resis
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Keywords: Circulating cell-free DNA; cfDNA; Taxane chemotherapy; PROSELICA; FIRSTANA; Cabazitaxel; Docetaxel;
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry
Keywords: Abiraterone; Cabazitaxel; Fatigue; Pain; Quality of life;
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis
Keywords: Castration resistant prostate cancer; Chemothreapy; Docetaxel; Estramustine; Cabazitaxel; Mitoxantrone; Network meta-analysis;
A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN)
Keywords: Cabazitaxel; Induction chemotherapy; Neoadjuvant therapy; Head and neck cancer; Squamous call carcinoma of head and neck; TPF;
Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer
Keywords: Cabazitaxel; Docetaxel; Head and neck cancer; Palliative; Chemotherapy; Second line;
Clinical TrialRandomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE
Keywords: Pathological complete response; Cabazitaxel; Paclitaxel; Breast cancer;
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
Keywords: Cabazitaxel; Castration-resistant prostate cancer; Circulating tumour cells; Dosing schedule; Toxicity;
Ultrasound Improves the Delivery and Therapeutic Effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts
Keywords: Drug delivery; Focused ultrasound; Microbubbles; Nanomedicine; Poly(alkyl cyanoacrylate); Cabazitaxel; Triple-negative breast cancer;
Cabazitaxel causes a dose-dependent central nervous system toxicity in rats
Keywords: Cabazitaxel; Central nervous system; Neurotoxicity; Rat;
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel
Keywords: Adverse event; Cabazitaxel; Castration-resistant prostate cancer; Clinical trial; Docetaxel;
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
Keywords: Androgen receptor; Cabazitaxel; Castration-resistant prostate cancer; Cross-resistance; Docetaxel; Enzalutamide; Taxanes;
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer
Keywords: Castration-resistant prostate cancer; Docetaxel; Cabazitaxel; Exosomes; P-glycoprotein/P-gp; Multidrug resistance protein 1/MDR1;
Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
Keywords: Enzalutamide; Metastatic castration-resistant prostate cancer; Abiraterone; Cabazitaxel; Docetaxel
Isostructurality Among Solvates of Cabazitaxel: X-ray Structures and New Solvates Preparation
Keywords: cabazitaxel; isostructurality; solvate; crystal structure; X-ray powder diffractometry; thermogravimetric analysis; pseudopolymorph;
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Keywords: AR-V7; Androgen receptor; Cabazitaxel; Castration-resistant prostate cancer; CellSearch; Circulating tumor cells; Metastatic prostate cancer
Prise en charge du cancer de prostate résistant à la castration métastatique
Keywords: Cancer de prostate résistant à la castration; Acétate d'abiratérone; Enzalutamide; Docétaxel; Cabazitaxel; Dénosumab; Alpharadin; Sipuleucel-T; Variants épissage; AR-V7; Metastatic castration-resistant prostate cancer; Abiraterone acetate; Enzalu
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
Keywords: Abiraterone acetate; Cabazitaxel; Castration-resistant prostate cancer; Enzalutamide; Fourth line; Prognostic factors; Third line;
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Keywords: Prostate cancer; Metastatic; Cabazitaxel; Abiraterone;
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
Keywords: Cabazitaxel; Phase 2; Small-cell lung cancer; Relapse; Topotecan;
Biological evaluation of new antitumor taxoids: Alteration of substitution at the C-7 and C-10 of docetaxel
Keywords: Paclitaxel; Antitumor; Analogues; Biological assays; Cabazitaxel;